Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00526812 | A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | PHASE1 | COMPLETED | 54 | — | — | Nov 30, 2005 | - | May 28, 2025 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| Group A (RTA 744) | EXPERIMENTAL | Receive study drug for three consecutive days, Cycle repeated every 21 days. |
| Group C (RTA 744 Injection) | EXPERIMENTAL | Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks. |
| Name | Type | Description |
|---|---|---|
| RTA 744 | DRUG | Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml. |
| RTA 744 injection | DRUG | Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks. |
Inclusion Criteria: * Prior histologically confirmed anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligo-astrocytoma, glioblastoma multiforme, or gliosarcoma, for whom no other effective therapy is available. * A prior histologic diagnosis of a lower grade of glioma is allo...